Logo image of BBIO

BRIDGEBIO PHARMA INC (BBIO) Stock Fundamental Analysis

NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD

45.195  -1.12 (-2.43%)

Fundamental Rating

3

Overall BBIO gets a fundamental rating of 3 out of 10. We evaluated BBIO against 553 industry peers in the Biotechnology industry. BBIO may be in some trouble as it scores bad on both profitability and health. BBIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BBIO had negative earnings in the past year.
BBIO had a negative operating cash flow in the past year.
In the past 5 years BBIO always reported negative net income.
BBIO had a negative operating cash flow in each of the past 5 years.
BBIO Yearly Net Income VS EBIT VS OCF VS FCFBBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

The Return On Assets of BBIO (-75.76%) is worse than 67.09% of its industry peers.
Industry RankSector Rank
ROA -75.76%
ROE N/A
ROIC N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBIO Yearly ROA, ROE, ROICBBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

BBIO has a Gross Margin of 95.35%. This is amongst the best in the industry. BBIO outperforms 95.30% of its industry peers.
BBIO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
BBIO Yearly Profit, Operating, Gross MarginsBBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BBIO has been increased compared to 1 year ago.
BBIO has more shares outstanding than it did 5 years ago.
BBIO has a better debt/assets ratio than last year.
BBIO Yearly Shares OutstandingBBIO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BBIO Yearly Total Debt VS Total AssetsBBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

BBIO has an Altman-Z score of -4.78. This is a bad value and indicates that BBIO is not financially healthy and even has some risk of bankruptcy.
BBIO has a Altman-Z score of -4.78. This is comparable to the rest of the industry: BBIO outperforms 40.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.78
ROIC/WACCN/A
WACC9.48%
BBIO Yearly LT Debt VS Equity VS FCFBBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 4.57 indicates that BBIO has no problem at all paying its short term obligations.
With a Current ratio value of 4.57, BBIO perfoms like the industry average, outperforming 49.55% of the companies in the same industry.
BBIO has a Quick Ratio of 4.54. This indicates that BBIO is financially healthy and has no problem in meeting its short term obligations.
BBIO has a Quick ratio of 4.54. This is comparable to the rest of the industry: BBIO outperforms 50.81% of its industry peers.
Industry RankSector Rank
Current Ratio 4.57
Quick Ratio 4.54
BBIO Yearly Current Assets VS Current LiabilitesBBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BBIO have decreased strongly by -17.08% in the last year.
The Revenue for BBIO has decreased by -41.71% in the past year. This is quite bad
BBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.48% yearly.
EPS 1Y (TTM)-17.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-340%
Revenue 1Y (TTM)-41.71%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%-44.76%

3.2 Future

The Earnings Per Share is expected to grow by 31.38% on average over the next years. This is a very strong growth
Based on estimates for the next years, BBIO will show a very strong growth in Revenue. The Revenue will grow by 60.93% on average per year.
EPS Next Y-4.05%
EPS Next 2Y14.97%
EPS Next 3Y25.93%
EPS Next 5Y31.38%
Revenue Next Year105.47%
Revenue Next 2Y75.25%
Revenue Next 3Y77.39%
Revenue Next 5Y60.93%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BBIO Yearly Revenue VS EstimatesBBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
BBIO Yearly EPS VS EstimatesBBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBIO Price Earnings VS Forward Price EarningsBBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBIO Per share dataBBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as BBIO's earnings are expected to grow with 25.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.97%
EPS Next 3Y25.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (7/30/2025, 3:26:08 PM)

45.195

-1.12 (-2.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners87.27%
Inst Owner Change-0.36%
Ins Owners4.31%
Ins Owner Change5.48%
Market Cap8.58B
Analysts82.4
Price Target63.78 (41.12%)
Short Float %11.92%
Short Ratio7.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.41%
Min EPS beat(2)-21.38%
Max EPS beat(2)6.56%
EPS beat(4)2
Avg EPS beat(4)9.76%
Min EPS beat(4)-21.38%
Max EPS beat(4)64.07%
EPS beat(8)3
Avg EPS beat(8)8.11%
EPS beat(12)5
Avg EPS beat(12)12.33%
EPS beat(16)6
Avg EPS beat(16)9.04%
Revenue beat(2)2
Avg Revenue beat(2)75.17%
Min Revenue beat(2)65.74%
Max Revenue beat(2)84.61%
Revenue beat(4)2
Avg Revenue beat(4)20.27%
Min Revenue beat(4)-40.46%
Max Revenue beat(4)84.61%
Revenue beat(8)3
Avg Revenue beat(8)167.07%
Revenue beat(12)4
Avg Revenue beat(12)123.7%
Revenue beat(16)5
Avg Revenue beat(16)83.96%
PT rev (1m)3.9%
PT rev (3m)12.59%
EPS NQ rev (1m)16.56%
EPS NQ rev (3m)30.97%
EPS NY rev (1m)-1.32%
EPS NY rev (3m)16.03%
Revenue NQ rev (1m)1.67%
Revenue NQ rev (3m)77.03%
Revenue NY rev (1m)2.62%
Revenue NY rev (3m)82.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 67.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.77
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-2.68
FCFYN/A
OCF(TTM)-2.64
OCFYN/A
SpS0.67
BVpS-8.68
TBVpS-8.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.35%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.36%
Cap/Sales 7.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.57
Quick Ratio 4.54
Altman-Z -4.78
F-Score2
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)86.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)8.73%
Cap/Sales(5y)27.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-340%
EPS Next Y-4.05%
EPS Next 2Y14.97%
EPS Next 3Y25.93%
EPS Next 5Y31.38%
Revenue 1Y (TTM)-41.71%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%-44.76%
Revenue Next Year105.47%
Revenue Next 2Y75.25%
Revenue Next 3Y77.39%
Revenue Next 5Y60.93%
EBIT growth 1Y-44.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.1%
EBIT Next 3Y30.23%
EBIT Next 5Y23.85%
FCF growth 1Y-24.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.12%
OCF growth 3YN/A
OCF growth 5YN/A